# GammaTile Raises $100M Series E After ASCO Data Showing 93% Tumor Recurrence Reduction

> financing · REPORTED · 2026-06-09

GT Medical Technologies raised an oversubscribed $100 million Series E on June 9, 2026 to advance commercial expansion of its FDA-cleared GammaTile bioresorbable radiotherapy brain tumor implant and fund the BRIDGES trial for newly diagnosed glioblastoma. Data presented at ASCO 2026 showed GammaTile reduced tumor recurrence risk by 93% and death risk by 41% at 12 months versus standard care.

- Company: GammaTile / GT Medical Technologies
- Sector: oncology
- Primary source: https://wewillcure.com/insights/news/funding-and-models/medtech-venture-funding-tracker

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.